The Board of Directors of Tyra Biosciences, Inc. approved an increase in the number of authorized directors from nine to ten. Habib J. Dable has been appointed as a Class II director, effective April 16, 2026. Mr. Dable's initial term will expire at the 2026 annual meeting of stockholders. The appointment includes a grant of options to purchase 44,400 shares of common stock, vesting in equal monthly installments over 36 months. Mr. Dable is classified as an independent director under Nasdaq listing requirements.